Following the success in establishing human induced pluripotent stem (iPS) cells, research into various applications of the cells derived from human iPS cells has begun in earnest. The use of iPS cell-derived cells in clinical therapies is one of the most exciting of the possible applications. However, the risk of tumorigenicity is the biggest potential obstacle to use iPS cell derivatives in the clinic. It should be noted that the human cells used to generate iPS cell lines may have acquired genetic mutations and these might influence the tumorigenicity of the cells. In particular, the cells of older people have a higher risk of genetic mutations than those of younger people. Here, we show that iPS cells could be derived from short-term cultures of neonatal tissues. The established human iPS cells expressed various markers of undifferentiated cells and formed teratoma in immunodeficient mice. The human iPS cells derived from neonatal tissues may represent a clinical material possessing less tumorigenicity.

中文翻译：

---

人新生儿组织诱导多能干细胞的建立。

随着人类诱导多能干细胞 (iPS) 细胞的成功建立，人类 iPS 细胞衍生细胞的各种应用研究已经开始认真开展。在临床治疗中使用 iPS 细胞衍生细胞是最令人兴奋的可能应用之一。然而，致瘤性风险是 iPS 细胞衍生物在临床上使用的最大潜在障碍。应该注意的是，用于产生 iPS 细胞系的人类细胞可能已经获得了基因突变，这些可能会影响细胞的致瘤性。尤其是老年人的细胞比年轻人的细胞发生基因突变的风险更高。在这里，我们表明 iPS 细胞可以来自新生儿组织的短期培养。建立的人类 iPS 细胞表达未分化细胞的各种标志物，并在免疫缺陷小鼠中形成畸胎瘤。来源于新生儿组织的人类 iPS 细胞可能代表了一种具有较低致瘤性的临床材料。